- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials | 1 | GlobeNewswire (USA) | ||
| 12.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing | 1 | GlobeNewswire (USA) | ||
| 10.03. | Calidi Biotherapeutics closes $6M public offering | 1 | Investing.com | ||
| 10.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option | 1 | GlobeNewswire (USA) | ||
| CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.03. | Calidi BioTherapeutics prices $5.2M underwritten public offering | 1 | Seeking Alpha | ||
| 06.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering | 2 | GlobeNewswire (USA) | ||
| 06.03. | Calidi Biotherapeutics (CLDI) Stock Plunges 35% After Hours - Here's Why | 1 | Benzinga.com | ||
| 06.03. | Calidi Biotherapeutics announces underwritten public offering | 1 | Investing.com | ||
| 06.03. | Calidi BioTherapeutics plans public offering of stock, pre-funded warrants; shares down | 1 | Seeking Alpha | ||
| 06.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Proposed Public Offering | 113 | GlobeNewswire (Europe) | SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic... ► Artikel lesen | |
| 05.12.25 | RedChip Companies, Inc.: Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 469 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / December 5, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on the RedChip... ► Artikel lesen | |
| 13.11.25 | Calidi BioTherapeutics GAAP EPS of -$2.21 misses by $0.53 | 1 | Seeking Alpha | ||
| 13.11.25 | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights | 468 | GlobeNewswire (Europe) | Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform... ► Artikel lesen | |
| 13.11.25 | Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11.25 | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11.25 | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 03.11.25 | Cha Biotech's Matica Bio, Calidi partner on cancer immunotherapy project | 2 | Korea Herald | ||
| 24.10.25 | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08.25 | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights | 339 | GlobeNewswire (Europe) | Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune... ► Artikel lesen | |
| 01.08.25 | RedChip Companies, Inc.: Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 620 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / August 1, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,10 | -0,59 % | Jetzt zuschlagen! Mit BioNTech, Vidac Pharma und Pfizer in die Krebsforschung investieren und Renditen sichern | Die globalen Gesundheitsausgaben explodieren und der Onkologie Sektor verspricht überdurchschnittliche Renditen. Während aufgrund einer immer älter werdenden Bevölkerung die Zahl der Krebsneuerkrankungen... ► Artikel lesen | |
| MODERNA | 45,525 | -1,70 % | Moderna Stock is Soaring. Is It Too Late to Buy? | ||
| OCUGEN | 1,710 | -0,20 % | Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% reductions... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,400 | +2,39 % | Why Viking Therapeutics Stock Could Take Off Later This Year | ||
| ABCELLERA BIOLOGICS | 2,884 | -2,40 % | AbCellera auf dem KeyBanc Forum: Strategische Fortschritte im Biotech-Sektor | ||
| ADAPTIMMUNE THERAPEUTICS | 0,007 | -59,38 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 3,920 | 0,00 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates | Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026... ► Artikel lesen | |
| QIAGEN | 34,940 | 0,00 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,605 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Addresses Misleading Short-Seller Report | RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 27,560 | +2,87 % | Block & Leviton LLP: Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses | Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have... ► Artikel lesen | |
| MAZE THERAPEUTICS | 31,800 | 0,00 % | Maze Therapeutics: BTIG bestätigt Kaufempfehlung nach positiven Studiendaten | ||
| APOGEE THERAPEUTICS | 78,55 | +7,63 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 35,550 | 0,00 % | Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts 'Upbeat' | ||
| BEAM THERAPEUTICS | 23,110 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| ARCELLX | 114,53 | -0,11 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme |
Das Unternehmen CALIDI BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,82 % bei einem Aktienkurs von 0,282 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALIDI BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.